Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
Follow GYRE
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
74.80 | 49.81 | 92.63 | 60.05 |
+8 more quarters Free account |
Receivables |
28.02 | 22.99 | 31.31 | 26.11 | |
Inventory |
11.43 | 11.35 | 10.17 | 8.85 | |
Other current assets |
— | — | 1.49 | 2.87 | |
Total current assets |
122.07 | 91.73 | 149.36 | 98.58 | |
Property, Plant, Equpment (Net) |
27.28 | 23.57 | 27.55 | 23.61 | |
Long-Term Investments |
28.44 | 29.42 | 23.52 | 20.32 | |
Goodwill and Intangible Assets (Total) |
4.53 | 4.63 | 4.73 | 4.85 | |
Long Term Assets (Tax, Deferred) |
9.28 | 7.72 | 6.87 | 6.71 | |
Long-term assets (Other) |
7.65 | 4.94 | 7.74 | 5.32 | |
Total non-current assets |
77.18 | 70.28 | 70.40 | 60.81 | |
Total Assets |
199.26 | 162.02 | 219.76 | 159.38 | |
Accounts Payable |
1.24 | 0.27 | 1.34 | 0.56 | |
Accrued Expenses |
18.81 | 15.42 | 18.16 | 11.80 | |
Current Part of Taxes to Pay |
2.15 | 3.13 | 2.94 | 2.65 | |
Other current liabilities |
— | — | 0.01 | 0.06 | |
Total current liabilities |
28.66 | 19.79 | 23.78 | 15.91 | |
Non-current Liabilities (Other) |
3.64 | 5.17 | 5.32 | 5.52 | |
Total non-current liabilities |
5.67 | 5.24 | 7.62 | 6.06 | |
Total liabilities |
34.34 | 25.03 | 31.40 | 21.97 | |
Additional Paid In Capital |
240.64 | 174.65 | 172.82 | 167.13 | |
Preferred Stock (Total) |
22.43 | — | 128.81 | — | |
Common Stock (Net) |
0.11 | 0.09 | 0.09 | 0.09 | |
Retained Earnings |
(137.96) | (77.67) | (112.60) | (66.70) | |
Shareholders Equity (Other) |
3.65 | 3.65 | 3.10 | 3.10 | |
Common Equity (Total) |
142.49 | 136.99 | 59.55 | 137.42 | |
Shareholders Equity (Total) |
164.92 | 136.99 | 188.36 | 137.42 | |
Shareholders Equity and Liabilities (Total) |
199.26 | 162.02 | 219.76 | 159.38 | |
Shares (Common) |
106.03 | 91.34 | 91.31 | 90.89 | |
Shares (Preferred) |
3.70 | — | 2.60 | — | |
Shareholders Equity (Tangible) |
160.39 | 132.36 | 183.63 | 132.57 | |
Net Debt |
(74.80) | (49.81) | (92.63) | (60.05) |